{"abstract": "The biotechnology company said Thursday that its experimental osteoporosis drug proved superior to Fosamax from Merck in a clinical trial.", "web_url": "https://www.nytimes.com/2008/01/25/business/25amgen.html", "snippet": "The biotechnology company said Thursday that its experimental osteoporosis drug proved superior to Fosamax from Merck in a clinical trial.", "lead_paragraph": "Amgen, the biotechnology company, said Thursday that its experimental osteoporosis drug, the brightest hope in its product pipeline, proved superior to Fosamax from Merck in a clinical trial. ", "print_section": "C", "print_page": "3", "source": "The New York Times", "multimedia": [], "headline": {"main": "Amgen Posts Weak Results, but Hails Osteoporosis Drug", "kicker": null, "content_kicker": null, "print_headline": "Amgen Posts Weak Results, But Hails Osteoporosis Drug", "name": null, "seo": null, "sub": null}, "keywords": [{"name": "organizations", "value": "Merck & Company Inc", "rank": 1, "major": "N"}, {"name": "subject", "value": "Company Reports", "rank": 2, "major": "N"}, {"name": "subject", "value": "Drugs (Pharmaceuticals)", "rank": 3, "major": "N"}, {"name": "organizations", "value": "Food and Drug Administration", "rank": 4, "major": "N"}, {"name": "organizations", "value": "AMGEN INC", "rank": 5, "major": "N"}], "pub_date": "2008-01-25T05:00:00+0000", "document_type": "article", "news_desk": "Business", "section_name": "Business Day", "byline": {"original": "By Andrew Pollack", "person": [{"firstname": "Andrew", "middlename": null, "lastname": "Pollack", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}], "organization": null}, "type_of_material": "News", "_id": "nyt://article/466eb8e5-4fed-5d6f-b498-b281ac7892b2", "word_count": 554, "uri": "nyt://article/466eb8e5-4fed-5d6f-b498-b281ac7892b2"}